Expression And Significance Of Rho BTB2Protein In Childhood Acute Lymphoblastic Leukemia

Objective:To study the expression and significance of Rho BTB2protein in childhood acute lymphoblastic leukemia (ALL). To explore the relationship and the significance between the Rho BTB2protein and Cyclin D1protein in childhood acute lymphoblastic leukemia.Methods:Bone marrow and peripheral blood (the percentage of blast cell is more than30%) of25ALL children was collected as the experimental group, which comprise21primary ALL and4relapseing ALL. Bone marrow of25ALL children after a period of standard chemotherapy was the therapeutic group. And the control group was bone marrow of20children without malignant hematopathy. Immunocytochemistry methods was used to determine the expression of Rho BTB2protein, and western blot method was used to prove the expression of Rho BTB2protein and CyclinD1protein. All of their clinical data was collected for statistical analysis.Results:The result of Immunohistochemistory method revealed that the Rho BTB2protein was located in the cytoplasm of mononuclear cells. The expression of Rho BTB2protein was often deleted in ALL,while low in control group.The expression of Rho BTB2protein was no differences between in bone marrow and peripheral blood in experimental group (P>0.05).The expression of Rho BTB2protein in experimental group was significantly lower than that of in therapeutic group and control group(P <0.0125, the standard of inspection and calibration α’=0.0125). But there was no differences between therapeutic group and control group(P>0.0125, the standard of inspection and calibration α’=0.0125).The expression of Rho BTB2protein in standard risk ALL (SR-ALL) was significantly higher than that of in middle risk ALL (MR-ALL) and high risk ALL(HR-ALL)(P<0.05).The expression of Rho BTB2protein had no correlation with age, sex, immunophenotype and WBC counts (P>0.05). The proportion of complete remission(CR) in Rho BTB2protein negative group and Rho BTB2protein positive group was no different (P>0.05)The result of Western blot showed no significantly difference with the result of immunohistochemistory methods about the expression of Rho BTB2protein. The expression of Rho BTB2protein was often deleted in ALL, while existed in control group. The expression of Cyclin D1protein was low in control group and often high in ALL.The expression of Rho BTB2protein and Cyclin D1protein was no differences between in bone marrow and peripheral blood (P>0.05).The expression of Rho BTB2protein in experimental group was significantly lower than that of in therapeutic group and control group (P <0.05). The expression of Rho BTB2protein in therapeutic group was significantly lower than that of in control group(P<0.05). But there was no differences between complete remission(CR) group and control group (P>0.05). The expression of Cyclin D1protein in experimental group was higher than that of in therapeutic group and control group (P<0.05), and there was no differences between in therapeutic group and control group (P>0.05).The expression of Rho BTB2protein in SR-ALL was significantly higher than that of in MR-ALL and HR-ALL (P<0.05). But there was no differences between MR-ALL and HR-ALL (P>0.05) The expression of Cyclin D1protein was no differences between in MR-ALL and (HR-ALL (P>0.05), the expression of Cyclin D1protein in SR-ALL is lower in HR-ALL (P<0.05), the expression of Cyclin D1protein in MR-ALL is lower in HR-ALL (P<0.05).The expression of Rho BTB2protein had no correlation with age, sex, immunophenotype and WBC counts (P>0.05). The expression of Cyclin D1protein had no correlation with age and sex (P>0.05), but the expression of Cyclin D1protein was well positively correlated to initial WBC counts (P<0.05).The expression of Rho BTB2protein in CR group was higher than that of in NR group (P<0.05). The expression of Cyclin D1protein in CR group was lower than that of in NR group (P<0.05).The standardized value of Rho BTB2protein and Cyclin D1protein had a significant negative correlation through Pearson correlation analysis (r=-0.662, P<0.01).Conclusions:The expression of Rho BTB2protein was deleted or trace in ALL before treatment, and related to the degree of clinical risk, the expression of Rho BTB2protein was significantly increased after treatment, therefore, the abnormal expression of Rho BTB2protein may be involved in the occurrence and development of acute lymphoblastic leukemia. The negative correlation between the level of the expression of Rho BTB2protein and Cyclin D1before treatment possibly suggest that the missing or trace of the Rho BTB2expression may down-regulate Cyclin D1becomes weaken in ALL, which may lead to the occurance of disease.